CONCLUSIONS AND FUTURE DIRECTIONS

The approval of docetaxel chemotherapy in prostate cancer treatment ushered in an era in which improvement in OS became a well-defined, achievable end point. However, resistance still occurs, and responses are limited in men with mCRPC. There is a continuing need to understand varying mechanisms of resistance and ways to overcome them. In order to better understand tumor biology and mechanisms of chemoresistance, pre- and postchemotherapy molecular analyses of tumor genomic material are critical. Additionally, the mechanisms of resistance to chemotherapy following administration of other classes of agents, such as anti-androgen agents, may also be applicable considering the cross-resistance between them. Rational selection of patients is also important to produce large increments and to develop precision medicine.


Continue Reading

Footnotes

ACADEMIC EDITOR: William Chi-shing Cho, Editor in Chief

PEER REVIEW: Ten peer reviewers contributed to the peer review report. Reviewers’ reports totaled 1840 words, excluding any confidential comments to the academic editor.

FUNDING: Guru Sonpavde gratefully acknowledges the research support extended to Department of Medicine, University of Alabama at Birmingham, by Onyx, Bayer, Boehringer-Ingelheim, Merck, Sanofi, Celgene, and Pfizer. The authors confirm that the funder had no influence over the study design, content of the article, or selection of this journal.

COMPETING INTERESTS: VL is an advisory board member for aHUS for Alexion. JBA-C is an advisory board member for Dendreon, Algeta/Bayer and AZD, and a member of the speakers’ bureau for BMS. GS discloses research support to his institution from Onyx, Bayer, Boehringer-Ingleheim, Merck, Sanofi, Celgene and Pfizer. GS is a consultant to Bayer, Pfizer, Novartis, Sanofi, Genentech, Agensys, Argos, Astrazeneca, Janssen and Eisai, and a speaker and author for Clinical Care Options and Uptodate.

Paper subject to independent expert blind peer review. All editorial decisions made by independent academic editor. Upon submission manuscript was subject to anti-plagiarism scanning. Prior to publication all authors have given signed confirmation of agreement to article publication and compliance with all applicable ethical and legal requirements, including the accuracy of author and contributor information, disclosure of competing interests and funding sources, compliance with ethical requirements relating to human and animal study participants, and compliance with any copyright requirements of third parties. This journal is a member of the Committee on Publication Ethics (COPE).


Vipin Lohiya,1 Jeanny B. Aragon-Ching,2 and Guru Sonpavde1

1Division of Hematology-Oncology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.

2INOVA Schar Cancer Institute, Fairfax, VA, USA.

CORRESPONDENCE: Email: [email protected]  


Author Contributions

Conceived and designed the experiments: GS, VL, JA. Analyzed the data: GS, VL, JA. Wrote the first draft of the manuscript: VL. Contributed to the writing of the manuscript: GS, VL, JA. Agree with manuscript results and conclusions: GS, VL, JA. Jointly developed the structure and arguments for the paper: GS, VL, JA. Made critical revisions and approved final version: GS, VL, JA. All authors reviewed and approved of the final manuscript.

REFERENCES

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66(1):7–30. [PubMed]

2. Chandrasekar T, Yang JC, Gao AC, Evans CP. Mechanisms of resistance in castration-resistant prostate cancer (CRPC) Transl Androl Urol. 2015;4(3):365–80. [PMC free article] [PubMed]

3. Antonarakis ES, Armstrong AJ. Evolving standards in the treatment of docetaxel-refractory castration-resistant prostate cancer. Prostate Cancer Prostatic Dis. 2011;14(3):192–205. [PMC free article] [PubMed]

4. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351(15):1502–12. [PubMed]

5. Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351(15):1513–20. [PubMed]

6. Culine S, Droz JP. Chemotherapy in advanced androgen-independent prostate cancer 1990–9: a decade of progress? Ann Oncol. 2000;11(12):1523–30. [PubMed]

7. Ravery V, Fizazi K, Oudard S, et al. The use of estramustine phosphate in the modern management of advanced prostate cancer. BJU Int. 2011;108(11):1782–6. [PubMed]

8. Fosså SD, Miller A. Treatment of advanced carcinoma of the prostate with estramustine phosphate. J Urol. 1976;115(4):406–8. [PubMed]

9. Eisenberger MA, Sinibaldi VW. The role of cytotoxic chemotherapy in prostate cancer. A critical reevaluation 20 years later. Oncology (Williston Park) 2006;20(8):853–62. discussion 863, 867–58. [PubMed]

10. Tannock IF, Osoba D, Stockler MR, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol. 1996;14(6):1756–64. [PubMed]

11. Kantoff PW, Halabi S, Conaway M, et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182study. J Clin Oncol. 1999;17(8):2506–13. [PubMed]

12. Ryan CJ, Smith MR, de Bono JS, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2013;368(2):138–48. [PMC free article] [PubMed]

13. Sternberg CN, Petrylak DP, Sartor O, et al. Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial. J Clin Oncol. 2009;27(32):5431–8. [PubMed]

14. de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364(21):1995–2005. [PMC free article] [PubMed]

15. Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367(13):1187–97. [PubMed]

16. Beer TM, Armstrong AJ, Rathkopf DE, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014;371(18):1755. [PubMed]

17. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363(5):411–22. [PubMed]

18. Parker C, Nilsson S, Heinrich D, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369(3):213–23. [PubMed]

19. de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010;376(9747):1147–54. [PubMed]

20. Scher HI, Morris MJ, Stadler WM, et al. Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the prostate Cancer Clinical Trials Working Group 3. J Clin Oncol. 2016;34(12):1402–18. [PMC free article] [PubMed]

21. Fitzpatrick JM, de Wit R. Taxane mechanisms of action: potential implications for treatment sequencing in metastatic castration-resistant prostate cancer. Eur Urol. 2014;65(6):1198–204. [PubMed]

22. Darshan MS, Loftus MS, Thadani-Mulero M, et al. Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer. Cancer Res. 2011;71(18):6019–29. [PMC free article] [PubMed]

23. Zhu ML, Kyprianou N. Androgen receptor and growth factor signaling crosstalk in prostate cancer cells. Endocr Relat Cancer. 2008;15(4):841–9. [PMC free article] [PubMed]

24. Komlodi-Pasztor E, Sackett D, Wilkerson J, Fojo T. Mitosis is not a key target of microtubule agents in patient tumors. Nat Rev Clin Oncol. 2011;8(4):244–50. [PubMed]

25. Petrylak DP, Ankerst DP, Jiang CS, et al. Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99–16. J Natl Cancer Inst. 2006;98(8):516–21. [PubMed]

26. Armstrong AJ, Garrett-Mayer E, Ou Yang YC, et al. Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer. J Clin Oncol. 2007;25(25):3965–70. [PubMed]

27. Beer TM, Ryan CW, Venner PM, et al. Intermittent chemotherapy in patients with metastatic androgen-independent prostate cancer: results from ASCENT, a double-blinded, randomized comparison of high-dose calcitriol plus docetaxel with placebo plus docetaxel. Cancer. 2008;112(2):326–30. [PubMed]

28. Ross RW, Beer TM, Jacobus S, et al. A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone-refractory prostate cancer who are refractory to docetaxel. Cancer. 2008;112(3):521–6. [PubMed]

29. Nakabayashi M, Sartor O, Jacobus S, et al. Response to docetaxel/carboplatin-based chemotherapy as first- and second-line therapy in patients with metastatic hormone-refractory prostate cancer. BJU Int. 2008;101(3):308–12. [PubMed]

30. Sweeney CJ, Chen YH, Carducci M, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med. 2015;373(8):737–46. [PMC free article] [PubMed]

31. James ND, Sydes MR, Mason MD, et al. Docetaxel and/or zoledronic acid for hormone-naïve prostate cancer: first overall survival results from STAMPEDE (NCT 00268476) J Clin Oncol. 2015;33(suppl 5 s) Abstr5001.

32. James ND, Sydes MR, Clarke NW, et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet. 2016;387(10024):1163–77. [PMC free article] [PubMed]

33. Gravis GB, Boher J-M, Joly F, et al. Androgen deprivation therapy (ADT) plus docetaxel (D) versus ADT alone for hormone-naïve metastatic prostate cancer (PCa): Long-term analysis of the GETUG-AFU 15 phase III trial. J Clin Oncol. 2015;33(suppl 7) abstr140.

34. Fizazi K, Faivre L, Lesaunier F, et al. Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial. Lancet Oncol. 2015;16(7):787–94. [PubMed]

35. Sandler HM, Hu C, Rosenthal SA, et al. A phase III protocol of androgen suppression (AS) and 3DCRT/IMRT versus AS and 3DCRT/IMRT followed by chemotherapy (CT) with docetaxel and prednisone for localized, high-risk prostate cancer (RTOG 0521) J Clin Oncol. 2015;33(suppl) abstrLBA5002.